ClinicalTrials.gg
RecruitingNCT07730190Updated Sep 15, 2026

A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors

A Phase 1 interventional study of TQB6426 for Injection in Advanced Malignancies, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Recruiting at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

TQB6426 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Preclinical studies have demonstrated its potent anti-tumor activity coupled with a favorable therapeutic safety window, which provides sufficient pharmacological and toxicological evidence to support the initiation of human clinical trials.

02

Conditions studied

  • Advanced Malignancies
03

In context

Lead sponsor

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. is the lead sponsor of 18 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Study participants voluntarily enroll in this study, sign the form, and demonstrate good treatment compliance.
  2. Age ranging from 18 to 75 years (calculated based on the date of informed consent signature).
  3. (ECOG) performance status score of 0 or 1.
  4. Estimated survival time exceeding 12 weeks.
  5. liver function score ≤ 7 points (Class B).
  6. Per v1.1 criteria, at least one evaluable tumor lesion must be identified as a target lesion. Lesions previously treated with local therapy (transarterial embolization, transarterial chemoembolization, transarterial radioembolization, surgery, radiofrequency ablation, microwave ablation, other thermal ablation, percutaneous ethanol injection, radiotherapy, etc.) may also serve as target lesions provided there is documented progression in such lesions.
  7. Participants must provide qualified tumor tissue specimens, or consent to submit archived tumor tissue samples, or undergo percutaneous core or surgical biopsy on previously unirradiated tumor lesions to supply specimens for central laboratory biomarker testing.
  8. Dose-escalation phase: Advanced solid tumors confirmed via histopathological or cytological examination with failure of prior standard systemic anti-tumor therapies.
  9. Dose-expansion phase: Glypican-3 (GPC3) positivity confirmed by immunohistochemistry (IHC); prior IHC test reports are acceptable.
  10. Hematology laboratory criteria (no blood transfusion/blood products or hematopoietic stimulating factor administration within 14 days prior to screening): (ANC) ≥ 1.5 × 10⁹/L; count ≥ 100 × 10⁹/L; ≥ 90 g/L.
  11. Serum biochemistry laboratory criteria: 1) (ALT) and Aspartate Aminotransferase (AST) ≤ 3 × (ULN); for patients with intrahepatic , ALT and AST ≤ 5 × ULN; 2) Total (TBIL) ≤ 3 × ULN (≤ 3 × ULN allowed for patients with Gilbert's syndrome); 3) Serum albumin ≥ 28 g/L; 4) Serum Creatinine (Cr) ≤ 1.5 × ULN, or estimated ≥ 50 mL/min calculated via the Cockcroft-Gault formula.
  12. Urinalysis criteria: Urine protein \< 2+ on routine urinalysis; if urine protein ≥ 2+, 24-hour urinary protein quantification must be confirmed ≤ 1.0 g.
  13. Coagulation function criteria: (PT), Activated Partial Thromboplastin Time (APTT), and International Normalized Ratio (INR) ≤ 1.5 × ULN (for patients without prior anticoagulant therapy).
  14. Thyroid function criteria: Thyroid-Stimulating Hormone (TSH) ≤ ULN; participants with abnormal TSH but normal free T3 and free T4 levels are eligible for enrollment.
  15. Women of must agree to use effective throughout the study and for 6 months after study completion, and have a negative serum pregnancy test within 7 days prior to enrollment. Male participants must agree to use effective contraception throughout the study and for 6 months following study completion.

Exclusion criteria

Exclusion Criteria:

  1. Exclusion Criteria Subjects satisfying any of the following criteria shall be excluded from this trial: Prior treatment with GPC3-targeted agents or other antibody-drug conjugates (ADCs) utilizing topoisomerase I inhibitors as cytotoxic payloads.
  2. Diagnosis of another malignant tumor within 5 years prior to the first study dose, or concurrent secondary at screening. Eligible exceptions are as follows: other malignancies cured by single surgical resection with a continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, papillary thyroid carcinoma, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive carcinoma), Tis (carcinoma in situ), T1 (tumor invading lamina propria)].
  3. Medical conditions interfering with intravenous injection or venous blood collection (including but not limited to active phlebitis, severe lymphedema, extensive cutaneous infection, etc.).
  4. Unresolved adverse toxicities higher than Grade 1 stemming from prior therapies, excluding alopecia, skin pigmentation, and toxicities deemed by the Investigator to carry no safety risks.
  5. Major surgical procedures, significant traumatic injuries within 4 weeks before the first dose, or persistent unhealed wounds/fractures.
  6. Any hemorrhagic event ≥ NCI CTCAE Grade 3 occurring within 4 weeks prior to the first administration of study drug.
  7. History of arterial or venous thromboembolic events within 6 months before the first dose, such as cerebrovascular accidents (including ), deep vein thrombosis, pulmonary embolism, or any other severe thromboembolism. (Note: Thrombosis related to implantable venous access ports, catheter-induced thrombosis, or superficial venous thrombosis shall not be categorized as "severe" thromboembolism.)
  8. Participants with active viral hepatitis and poor disease control are excluded. Participants meeting the following criteria may be screened: -positive participants must have a quantitative HBV DNA level \<2000 IU/mL (or 10000 copies/mL), and participants shall receive anti-HBV therapy throughout the entire study period. Participants with infection requiring treatment may receive approved antiviral therapy during the study.
  9. Imaging confirmation of inferior vena cava tumor thrombus, complete occlusion of the main portal vein (tumor thrombus or blood thrombus), concurrent tumor thrombus invasion of the main portal vein plus primary branches, or portal vein tumor thrombus extending into the superior mesenteric vein, splenic vein or more proximal vessels.
  10. Peptic ulcer disease or inflammatory bowel disease.
  11. Active syphilis infection requiring clinical treatment.
  12. Active pulmonary tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis/radiation pneumonitis requiring treatment, symptomatic active pneumonia; prior interstitial lung disease (ILD) that required intervention or current ILD.
  13. History of untreatable psychoactive substance abuse or diagnosed psychiatric disorders.
  14. Candidates scheduled for bone marrow transplantation or solid organ transplantation, or those who have received such transplantations previously.
  15. Documented history of hepatic encephalopathy.
  16. Subjects with any severe and/or uncontrolled underlying diseases, including:

1) Uncontrolled hypertension (systolic BP ≥ 150 mmHg or diastolic BP ≥ 100 mmHg); 2) Poorly managed cardiac symptoms or disorders: a. Myocardial ischemia or myocardial infarction ≥ Grade 2, congestive heart failure ≥ Class II; b. Myocardial infarction within the past 12 months; c. Arrhythmias: Fridericia- interval (QTcF) > 450 msec in males and > 470 msec in females. If QTcF is abnormal, three serial measurements separated by at least 2 minutes shall be performed and the average value adopted; frequent ventricular premature contractions, significant sinus bradycardia, or other conditions assessed by the Investigator and relevant departments to confer high risk of malignant arrhythmia, or other conditions judged by the Investigator to predispose to malignant arrhythmia.

3) Active or uncontrolled severe infections (≥ NCI CTCAE Grade 2 infection); 4) Evidence of bleeding diathesis or severe coagulopathy; 5) Current or recent use (within 10 days prior to first study treatment) of aspirin (>325 mg/day), dipyridamole, ticlopidine, clopidogrel, cilostazol, or other anticoagulant/antiplatelet agents; 6) Renal failure requiring hemodialysis or peritoneal dialysis; 7) History of immunodeficiency, including positivity or other acquired/congenital immunodeficiency disorders; 8) Subjects requiring , systemic hormones, or absorbable topical hormones for immunosuppressive purposes and continuing such treatment within 7 days before the first dose (excluding at a daily dose equivalent to \<10 mg prednisone); 9) Diagnosed epilepsy requiring ongoing treatment; 10) Poorly controlled diabetes (fasting blood glucose [FBG] > 10 mmol/L); 11) History of gastrointestinal hemorrhage within 6 months before the first dose; portal hypertension with high bleeding risk as assessed by the Investigator, or positive red color sign on gastroscopy.

(17) Tumor-related symptoms and prior anti-tumor therapies:

  1. Subjects who received chemotherapy or immunotherapy within 2 weeks before the first dose, endovascular interventional therapy, local ablation, radiotherapy or small-molecule targeted agents within 2 weeks before the first dose, or remain within 5 half-lives of the last administered drug (the shorter time frame shall prevail). The shall be calculated from the date of completion of the last prior anti-tumor treatment.
  2. Treatment with Chinese patent medicines with anti-tumor indications clearly stated in NMPA-approved labeling within 2 weeks before the first dose (including Compound Mylabris Capsules, Kang'ai Injection, Kanglaite Capsules/Injection, Aidi Injection, Brucea Javanica Oil Injection/Capsules, Xiaoaiping Tablets/Injection, Huachansu Capsules, etc.).
  3. CT/MRI imaging showing tumor invasion into major blood vessels, or tumors assessed by the Investigator to have high risk of invading critical vessels and triggering fatal massive hemorrhage during the trial (e.g., tumors adjacent to or encasing the pulmonary artery or aorta).
  4. Uncontrolled pleural effusion, pericardial effusion, or moderate to severe ascites requiring repeated drainage.
  5. Severe biliary obstruction (excluding subjects with total ≤ 2 × after endoscopic stenting, percutaneous transhepatic biliary drainage or other interventions).
  6. Confirmed spinal cord compression, pathological fractures of weight-bearing bones, extensive bone , or intractable tumor-related bone pain.
  7. Carcinomatous meningitis, symptomatic , or brain metastases with symptom control lasting less than 4 weeks. 8) Spontaneous tumor rupture or high risk of impending tumor rupture.

(18) Known to the study drug or its . (19) Participation in another clinical trial of anti-tumor products with study drug administration within 4 weeks before the first dose.

(20) Lactating female subjects. (21) Any condition judged by the Investigator to pose substantial safety risks to the subject or impair the subject's ability to complete the trial.

Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (estimated)

Study arms

  • Experimental
    TQB6426 Dose Escalation and Expansion

    This arm includes two phases: Dose Escalation Phase (Phase Ia): Treatment regimen is TQB6426 for Injection via intravenous infusion (IV) on Day 1, every 3 weeks (Q3W). An accelerated titration design combined with a "Rolling 6" dose-escalation approach was adopted. Dose Expansion Phase (Phase Ib): The study dose will be finalized according to the results from Phase Ia, administered intravenously on Day 1 every 3 weeks (Q3W).

    Drug: TQB6426 for Injection

Interventions

  • DrugTQB6426 for Injection

    TQB6426 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Preclinical studies have demonstrated its potent anti-tumor activity coupled with a favorable therapeutic safety window, which provides sufficient pharmacological and toxicological evidence to support the initiation of human clinical trials.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT)

    Study participants experienced protocol-specified adverse events related to the investigational drug within one cycle (21 days) of receiving the investigational drug.

    Time frame: Baseline to 21 days

  2. Maximum Tolerated Dose

    The highest dose at which less than 33% of study participants experience dose-limiting toxicity (DLT)

    Time frame: Baseline to the end of the first treatment cycle (each cycle is 21 days)

  3. Recommended Phase II Dose

    The dose level of TQB6426 recommended for the further clinical trail studies based on assessment of the safety, efficacy and PK data from this study.

    Time frame: Baseline to study completion (up to 24 months).

  4. Incidence and severity of adverse events (AEs)

    Incidence and severity of adverse events (AEs)

    Time frame: up to 24 months

  5. Maximum Administered Dose

    MAD is defined to be reached if, following the pre-specified dose escalation, a dose-exposure plateau is achieved as judged by PK data, or further dose escalation carries substantial safety risks or subjects cannot tolerate continued dose increase based on available safety data, or model analysis indicates that the optimal safe and effective target dose has been explored.

    Time frame: Baseline to the end of the first treatment cycle (each cycle is 21 days)

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Cmax refers to the maximum drug concentration in plasma after administration.

    Time frame: up to 24 months

  2. Area under the plasma drug concentration-time curve from time zero to the time of the last accurately quantifiable concentration (AUC0-t)

    AUC0-t refers to the total systemic exposure to the drug from the time of administration until the last accurately quantifiable concentration is observed.

    Time frame: up to 24 months

  3. Area under the plasma concentration-time curve extrapolated from time zero to infinite time(AUC0-∞)

    AUC0-∞ refers to the total systemic exposure to the drug from the time of administration to infinite time .

    Time frame: up to 24 months

  4. Time to peak concentration (Tmax)

    The time from drug administration to the time point of the maximum observed plasma drug concentration.

    Time frame: up to 24 months

  5. Terminal Elimination Rate Constant(λz)

    First-order rate constant governing the elimination of drug from plasma during the terminal log-linear elimination phase.

    Time frame: up to 24 months

  6. Terminal Elimination Half-Life (t1/2)

    The time required for the plasma drug concentration to decrease by one-half during the terminal elimination phase.

    Time frame: up to 24 months

  7. Apparent Clearance (CL)

    Apparent clearance following extravascular administration, calculated as Dose / AUC0-∞

    Time frame: up to 24 months

  8. Apparent Volume of Distribution (Vd)

    Volume of Distribution (Vd) is a pharmacokinetic parameter that refers to the ratio of the total amount of drug in the body to its plasma concentration when the drug reaches a dynamic equilibrium in the body.

    Time frame: up to 24 months

  9. Percentage of extrapolated AUC0-∞ (%AUCextrap)

    The percentage of AUC0-∞ extrapolated refers to the percentage of the area extrapolated from the last accurately quantifiable concentration to infinity (AUCextrap) relative to the total AUC0-∞. It is used to evaluate the reliability of the AUC0-∞ estimation.

    Time frame: up to 24 months

  10. Incidence of anti-drug antibodies (ADAs)

    Anti-drug antibodies (ADAs) are immune system-produced antibodies that specifically bind to therapeutic drugs (especially biologics or monoclonal antibodies). The development of ADAs can alter the drug's pharmacokinetics, reduce its clinical efficacy, or cause safety issues such as hypersensitivity reactions.

    Time frame: up to 24 months

  11. Objective Response Rate(ORR)

    The proportion of subjects with confirmed complete response (CR) or partial response (PR).

    Time frame: up to 24 months

  12. Duration of Response (DOR)

    The time from the date of first confirmed complete response (CR) or partial response (PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.

    Time frame: up to 24 months

  13. Disease Control Rate(DCR)

    The proportion of subjects achieving complete response, partial response or stable disease.

    Time frame: up to 24 months

  14. Progression-Free Survival (PFS)

    The time from the first dose of study drug to the date of first documented disease progression or death from any cause, whichever occurs first.

    Time frame: up to 24 months

  15. Overall Survival(OS)

    The time from first dose of study drug to date of death from any cause.

    Time frame: up to 24 months

07

Study locations

1 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 28, 2026
StartActual
Aug 25, 2026
Primary completionEst.
Aug 2027
CompletionEst.
May 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07730190
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Aug 25, 2026
Primary completion
Aug 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Qiang Xia, Doctor
Contact
Xiaqiang@medmail.com.cn
13661889035

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion